3 US Penny Stocks Under $200M Market Cap To Watch

As the U.S. stock market experiences fluctuations, with technology shares recently sliding and major indices taking a breather from their record highs, investors are on the lookout for new opportunities. Penny stocks, often representing smaller or newer companies, might seem like a term from bygone trading days but continue to hold relevance due to their potential for growth when backed by strong fundamentals. This article will explore three such penny stocks that stand out for their financial resilience and potential to uncover hidden value amidst current market conditions.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.802475	$5.83M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$145.67M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
PHX Minerals (NYSE:PHX)	$3.72	$139.43M	★★★★★☆
ZTEST Electronics (OTCPK:ZTST.F)	$0.22	$8.1M	★★★★★★
LexinFintech Holdings (NasdaqGS:LX)	$4.90	$805.62M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.58	$52.14M	★★★★★★
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.952	$85.62M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.84	$410.03M	★★★★☆☆

Click here to see the full list of 712 stocks from our US Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Tuniu (NasdaqGM:TOUR)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Tuniu Corporation is an online leisure travel company in China with a market cap of $135.12 million.

Operations: The company generates revenue primarily from its travel services segment, amounting to CN¥503.03 million.

Market Cap: $135.12M

Tuniu Corporation, with a market cap of US$135.12 million, primarily earns revenue from its travel services segment, totaling CN¥503.03 million. Despite being unprofitable, Tuniu has reduced its losses over the past five years by 38.1% annually and maintains more cash than total debt. The company's short-term assets significantly exceed both short- and long-term liabilities, indicating financial stability despite volatility in share price and earnings forecasts predicting 58.01% annual growth. A recent agreement with the Tourism Authority of Thailand may enhance Tuniu's prospects in popular travel markets for Chinese tourists.

• Click here and access our complete financial health analysis report to understand the dynamics of Tuniu.
• Understand Tuniu's earnings outlook by examining our growth report.

Allakos (NasdaqGS:ALLK)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Allakos Inc. is a clinical-stage biotechnology company focused on developing therapeutics targeting immunomodulatory receptors on immune effector cells for treating allergy, inflammatory, and proliferative diseases in the United States, with a market cap of $90.24 million.

Operations: Allakos Inc. currently does not report any revenue segments as it is a clinical-stage biotechnology company focused on developing therapeutics for allergy, inflammatory, and proliferative diseases in the United States.

Market Cap: $90.24M

Allakos Inc., with a market cap of US$90.24 million, is a pre-revenue clinical-stage biotechnology company focused on developing therapeutics for allergy and inflammatory diseases. Recent Phase 1 trial data for its AK006 treatment in chronic spontaneous urticaria showed promising safety and receptor occupancy results, but the company remains unprofitable with significant net losses reported. The stock has experienced high volatility, and shareholders have faced dilution over the past year. Financially, Allakos has short-term assets exceeding liabilities but less than a year of cash runway, which may impact its operational sustainability without additional funding or revenue generation.

• Dive into the specifics of Allakos here with our thorough balance sheet health report.
• Examine Allakos' earnings growth report to understand how analysts expect it to perform.

Baozun (NasdaqGS:BZUN)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Baozun Inc. offers comprehensive e-commerce solutions to brand partners in China and has a market cap of approximately $0.16 billion.

Operations: The company's revenue is primarily derived from its E-Commerce segment, which generated CN¥7.93 billion, and the Brand Management segment, contributing CN¥1.40 billion.

Market Cap: $161.44M

Baozun Inc., with a market cap of US$160 million, has shown resilience in the e-commerce sector despite being unprofitable. The company reported Q3 2024 revenue of CN¥2.06 billion, up from CN¥1.82 billion a year ago, while reducing its net loss to CN¥88.07 million from CN¥126.43 million year-over-year. Baozun's strategic share buybacks have reduced outstanding shares by 5.95%, reflecting management's confidence in its valuation, which trades significantly below estimated fair value. The company's strong cash position covers both short and long-term liabilities comfortably, providing a runway exceeding three years based on current free cash flow levels.

• Take a closer look at Baozun's potential here in our financial health report.
• Gain insights into Baozun's future direction by reviewing our growth report.

Taking Advantage

• Click through to start exploring the rest of the 709 US Penny Stocks now.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com